The company says its new harmonised listing structure will merely make it easier for those US funds that aren't allowed to own American depositary receipts (ADRs, a wrapper provided by a handful of banks for US investors) to get their hands on full-fat AstraZeneca stock. A global listing for global investors in a global company, as the cheerful corporate spin put it. But this definitely is not a moment to accentuate the positive.